Venous Thromboembolism in Medical Patients-The Scope of the Problem

 

 Buy Article Permissions and Reprints

ABSTRACT

The risk of venous thromboembolism (VTE) in medical patients has been substantially underestimated and prophylaxis is used far less than it is in surgical patients, reflecting the scarcity of evidence supporting antithrombotic therapy in nonsurgical settings.

Reports of the frequency of deep venous thrombosis (DVT) in general medical patients in the absence of prophylaxis vary from 10 to 26%, depending on the methods used for diagnosis of DVT and the patient population studied. The risk in specific groups may be higher and may exceed that reported in low- or moderate-risk surgical patients. Data from several studies show that DVT developed in ~55% of patients with stroke, 24% of patients with myocardial infarction, and, in general medical populations, congestive heart failure, respiratory distress and/or underlying chest infections appeared to increase the risk of VTE. The frequency of VTE in patients with congestive heart failure has been reported to be as high as 40%. In a study among patients in a medical intensive care unit, it was found that 33% had VTE, of which 48% were proximal leg thromboses.

Many other medical conditions increase the risk of thromboembolic events. These include malignant disease, which is commonly associated with a hypercoagulable state; inflammatory conditions such as systemic lupus erythematosus and inflammatory bowel disease; coma; and nephrotic syndrome.

Accurate risk assessment and prompt implementation of appropriate prophylaxis, selected on the basis of evidence from well-designed, controlled clinical trials, may reduce future morbidity and mortality due to VTE in medical patients.

REFERENCES

• 1 Goldhaber S Z. Clinical overview of venous thromboembolism.  Vasc Med . 1998;  3 35-40
  CrossrefPubMedGoogle Scholar
• 2 Stratton M A, Anderson F A, Bussey H I. et al . Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.  Arch Intern Med . 2000;  160 334-340
  CrossrefPubMedGoogle Scholar
• 3 Sandler D A, Martin J F. Autopsy-proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?.  J R Soc Med . 1989;  82 203-205
  CrossrefPubMedGoogle Scholar
• 4 Anderson Jr A F, Wheeler H B. Physician practices in the management of venous thromboembolism: a community-wide survey.  J Vasc Surg . 1992;  16 707-714
  PubMedGoogle Scholar
• 5 Goldhaber S Z, Hennekens C H, Evans D A, Newton E C, Godleski J J. Factors associated with correct antemortem diagnosis of major pulmonary embolism.  Am J Med . 1982;  73 822-826
  CrossrefPubMedGoogle Scholar
• 6 Nicolaides A N, Breddin H K, Fareed J. et al . Prevention of venous thromboembolism.  International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol . 2001;  20 1-37
  PubMedGoogle Scholar
• 7 Geerts W H, Heit J A, Clagett G P. et al . Prevention of venous thromboembolism.  Chest . 2001;  119(suppl 1) 132S-175S
  CrossrefPubMedGoogle Scholar
• 8 Hirsh D R, Ingenito E P, Goldhaber S Z. Prevalence of deep venous thrombosis among patients in medical intensive care.  JAMA . 1995;  274 335-337
  CrossrefPubMedGoogle Scholar
• 9 Fraisse F, Holzapfel L, Couland J M. et al . Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.  Am J Respir Crit Care Med . 2000;  161 1109-1114
  CrossrefPubMedGoogle Scholar
• 10 Samama M M, Cohen A T, Darmon J Y. et al . A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.  N Engl J Med . 1999;  341 793-800
  CrossrefPubMedGoogle Scholar
• 11 Mismetti P, Laporte-Simitsidis S, Tardy B. et al . Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.  Thromb Haemost . 2000;  83 14-19
  PubMedGoogle Scholar
• 12 Yirchow R. Phlogose und Thrombose im Gefässystem. Gesammelte Abhandlungen Eur Wissenschaftlichen Medicin Berlin: von Meininger III 1856: 458-635
  Google Scholar
• 13 Jafri S M, Ozawa T, Mammen E. et al . Platelet function, thrombin and fibrinolytic activity in patients with heart failure.  Eur Heart J . 1993;  14 205-212
  PubMedGoogle Scholar
• 14 Silverstein M D, Heit J A, Mohr D N. et al . Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25 years population-based study.  Arch Intern Med . 1998;  158 585-593
  CrossrefPubMedGoogle Scholar
• 15 Martinelli I. Risk factors for venous thromboembolism.  Thromb Haemost . 2001;  86 395-403
  PubMedGoogle Scholar
• 16 Heit J A, Silverstein M D, Mohr D N. et al . The epidemiology of venous thromboembolism in the community.  Thromb Haemost . 2001;  86 452-463
  PubMedGoogle Scholar
• 17 Anderson F A, Wheeler H B, Goldberg R J. et al . A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.  Arch Intern Med . 1991;  151 933-938
  CrossrefPubMedGoogle Scholar
• 18 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP study group. Groupe d'étude de la thrombose de Bretagne Occidentale.  Thromb Haemost . 2000;  83 657-660
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton L J. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population based, cohort study.  Arch Intern Med . 1999;  159 445-453
  CrossrefPubMedGoogle Scholar
• 20 Tracy R P, Bovill E G, Fried L P. et al . The distribution of coagulation factors VII and VIII in adults over 65 years. Results from the Cardiovascular Health Study.  Ann Epidemiol . 1992;  2 509-519
  CrossrefPubMedGoogle Scholar
• 21 Ershler W B. Interleukin-6: a cytokine for gerontologists.  J Am Geriatr Soc . 1993;  41 176-181
  CrossrefPubMedGoogle Scholar
• 22 Brozovic M, Chakrabarti R, Stirling Y. et al . Factor V in an industrial population.  Br J Haematol . 1976;  33 543-550
  PubMedGoogle Scholar
• 23 Köster T, Blann D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII and effect of von Willebrand factor on occurrence of deep-vein thrombosis.  Lancet . 1995;  345 152-155
  CrossrefPubMedGoogle Scholar
• 24 Lowe G D, Rumley A, Woodward M. et al . Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey. Illustrative reference ranges by age, sex and hormone use.  Br J Haematol . 1997;  97 775-784
  CrossrefPubMedGoogle Scholar
• 25 Bauer K A, Weiss L M, Sparrow D, Vokonas P S, Rosenberg R D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.  J Clin Invest . 1987;  80 1527-1534
  CrossrefPubMedGoogle Scholar
• 26 Ofosu F A, Craven S, Dewar L. et al . Age-related changes in factor VII proteolysis in vivo.  Br J Haematol . 1996;  94 407-412
  CrossrefPubMedGoogle Scholar
• 27 Wilkerson W R, Sane D C. Aging and thrombosis.  Semin Thromb Hemost . 2002;  28 555-567
  Article in Thieme ConnectPubMedGoogle Scholar
• 28 Sakkinen P A, Cushman M, Psaty B M. et al . Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort.  Thromb Haemost . 1998;  80 134-139
  PubMedGoogle Scholar
• 29 Gleerup G, Winther K. The effect of aging on platelet function and fibrinolytic activity.  Angiology . 1995;  46 715-718
  CrossrefPubMedGoogle Scholar
• 30 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.  J Am Coll Cardiol . 1987;  9 263-268
  CrossrefPubMedGoogle Scholar
• 31 Schatteman K A, Goossens F J, Scharpe S S, Neels H M, Hendriks D F. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.  Clin Chem . 1999;  45 807-813
  PubMedGoogle Scholar
• 32 Cogo A, Bernardi E, Prandoni P. et al . Acquired risk factors for deep-vein thrombosis in symptomatic outpatients.  Arch Intern Med . 1994;  154 164-168
  CrossrefPubMedGoogle Scholar
• 33 Grady D, Wenger N K, Herrington D. et al . Postmenopausal hormone therapy increases the risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study.  Ann Intern Med . 2000;  132 689-696
  PubMedGoogle Scholar
• 34 Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton L J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based, case-control study.  Arch Intern Med . 2000;  160 809-815
  CrossrefPubMedGoogle Scholar
• 35 Agnelli G. Venous thromboembolism and cancer: a two-way clinical association.  Thromb Haemost . 1997;  78 117-120
  PubMedGoogle Scholar
• 36 Ambrus J L, Ambrus C M, Mink I B, Pickren J W. Causes of death in cancer patients.  J Med . 1975;  6 61-64
  PubMedGoogle Scholar
• 37 Johnson M J, Sherry K. How do palliative physicians manage venous thromboembolism?.  Palliat Med . 1997;  11 462-468
  CrossrefPubMedGoogle Scholar
• 38 Scates S M. Diagnosis and treatment of cancer-related thrombosis.  Semin Thromb Hemost . 1992;  18 373-379
  PubMedGoogle Scholar
• 39 Harrington K J, Bateman A R, Syrigos K N. et al . Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis.  Ann Oncol . 1997;  8 669-673
  CrossrefPubMedGoogle Scholar
• 40 Orth S R, Ritz E. The nephrotic syndrome.  N Engl J Med . 1998;  338 1202-1211
  CrossrefPubMedGoogle Scholar
• 41 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.  Arch Intern Med . 2000;  160 3415-3420
  CrossrefPubMedGoogle Scholar
• 42 Haas S. Venous thromboembolic risk and its prevention in hospitalized medical patients.  Semin Thromb Hemost . 2002;  28 577-583
  Article in Thieme ConnectPubMedGoogle Scholar